Herpes‐like skin lesion after AstraZeneca vaccination for COVID‐19: A case report

Ardalan, Mohammadreza; Moslemi, Hamidreza; Shafiei, Shervin; Moselmi, Mohammadreza

doi:10.1002/ccr3.4883

Cited by 22 publications

(7 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…psoriasis, 103 , 133 , 137 , 141 , 215 , 239 , 248 , 252 , 282 , 312 bullous pemphigoid, 63 , 111 pemphigus vulgaris, 111 , 121 lichen planus, 85 , 164 , 245 cutaneous vasculitis, 163 vitiligo 293 and cutaneous lupus erythematosus 156 , 188 , 236 ) and viral reactivation (e.g. herpes zoster 74 , 81 , 85 , 92 , 99 , 100 , 102 , 107 , 108 , 113 , 116 , 131 , 191 , 268 ). In addition, more severe but rare reactions such as anaphylaxis 15 , 37 , 38 , 40 , 41 , 44 , 123 and severe cutaneous adverse reactions (SCARs) 136 , 185 , 231 , 271 have been reported as well.…”

Section: Discussionmentioning

confidence: 99%

Global prevalence and clinical manifestations of cutaneous adverse reactions following COVID‐19 vaccination: A systematic review and meta‐analysis

Washrawirul

Triwatcharikorn

Phannajit

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

Although vaccination is widely accepted as an effective method of preventing and controlling the COVID‐19 pandemic, many people are concerned about possible cutaneous side‐effects, which can delay or prevent them from being vaccinated. The objectives of this systematic review were to assess the global prevalence and clinical manifestations of cutaneous adverse reactions following COVID‐19 vaccination. PubMed and Scopus databases were searched for articles published from 1 January 2019 to 31 December 2021, and reference lists for each selected article were screened. Case reports, case series, observational studies and randomized controlled trials that provided information on cutaneous adverse reactions following COVID‐19 vaccines were included. A total of 300 studies were included in a systematic review of which 32 studies with 946 366 participants were included in the meta‐analysis. The pooled prevalence of cutaneous manifestations following COVID‐19 vaccination was 3.8% (95% CI, 2.7%–5.3%). COVID‐19 vaccines based on the mRNA platform had a higher prevalence than other platforms at 6.9% (95% CI, 3.8%–12.3%). Various cutaneous manifestations have been reported from injection site reactions, which were the most common (72.16%) to uncommon adverse reactions such as delayed inflammatory reactions to tissue filler (0.07%) and flares of pre‐existing dermatoses (0.07%). Severe cutaneous reactions such as anaphylaxis have also been reported, but in rare cases (0.05%). In conclusion, cutaneous adverse reactions are common, especially in those receiving mRNA vaccines. Most reactions are mild and are not contraindications to subsequent vaccination except for anaphylaxis, which rarely occurs. COVID‐19 vaccination may also be associated with flares of pre‐existing dermatoses and delayed inflammatory reactions to tissue filler. Patients with a history of allergies, pre‐existing skin conditions or scheduled for filler injections should receive additional precounselling and monitoring. A better understanding of potential side‐effects may strengthen public confidence in those wary of new vaccine technologies.

show abstract

Section: Discussionmentioning

confidence: 99%

Global prevalence and clinical manifestations of cutaneous adverse reactions following COVID‐19 vaccination: A systematic review and meta‐analysis

Washrawirul

Triwatcharikorn

Phannajit

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…We analyzed 93 cases of VZV reactivation following the COVID‐19 vaccine reported in literature. 1 , 2 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 We decided to focus only on cases with enough information to allow for a correct risk assessment, for example, we did not include all the reports where age or sex were not present. There was no significant difference between males and females (44 men vs 49 women), and, in accordance with the previous observations, 3 the majority of the VZV reactivations were secondary to mRNA vaccines (46 following Pfizer's BNT162b2 and 19 following Moderna's mRNA‐1273 vs 18 following Astrazeneca's AZD1222 (ChAdOx1), 2 following Johnson & Johnson's JNJ‐78436735 (Ad26.COV2.S), 1 following Bharat Biotech's BBV152 (Covaxin), 1 following Sinopharm's BBIBP‐CorV vaccine (Vero Cells), and 1 following Sputnik V (Gam‐COVID‐Vac); 5 not specified).…”

Section: Tablementioning

confidence: 99%

Potential risk factors for Varicella‐zoster virus reactivation after COVID‐19 vaccination

Lee

Macchi

Mora

et al. 2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

“…There was also an increase in cases of herpes simplex and herpes zoster after anti‐COVID‐19 vaccines, 26,39,50,51 reinforcing the hypothesis of immune dysregulation or immunomodulation that can also be caused by other vaccines such as trivalent influenza, H1N1, hepatitis A and rabies vaccines 52 …”

Section: Reviewmentioning

confidence: 80%

“…[47][48][49] There was also an increase in cases of herpes simplex and herpes zoster after anti-COVID-19 vaccines, 26,39,50,51 reinforcing the hypothesis of immune dysregulation or immunomodulation that can also be caused by other vaccines such as trivalent influenza, H1N1, hepatitis A and rabies vaccines. 52 The mechanism of the immune response to vaccines, which would lead to the reactivation of other viruses, is still not fully Note: Adapted from Griffith et al, 28 Flodin, 29 Gaby, 30 and HowMany.wiki: https://www.howmany.wiki/vw/--1--cup--of--uncooked-oats--in--gram elucidated. The main hypothesis would be that herpesvirus reactivation would result from failures in the innate or cell-mediated immune response, initiated by vaccination.…”

Section: What This Study Addsmentioning

confidence: 99%

L‐lysine: Its antagonism with L‐arginine in controlling viral infection. Narrative literature review

Pedrazini

Silva²,

Groppo

2022

Brit J Clinical Pharma

View full text Add to dashboard Cite

Knowledge about viral characteristics, mechanisms of entry into the host cell and multiplication/dissemination can help in the control and treatment of viral pathologies. Several nutritional factors linked to the host may favour viral multiplication and their control, may lead to new prophylactic alternatives and/or antiviral therapies.The objective of this review is to discuss the relationship between the amino acid Llysine and the control of viral infections, aiming at a possible therapeutic property.This research used databases such as PubMed, Web of Science, Scielo, Medline and Google Scholar, as well as searching for references cited by journals. The time frame covered the period between 1964 and January 2022. The observed studies have shown that the usual antiviral therapies are not able to interfere with the viruses in their latent state; however, they can interfere with the adhesion and fusion of viral particles or the production of proteins, which play an important role in viral epidemiology and control, particularly in the initial moment and in reactivation. Lysine is an amino acid that can interfere mainly in the formation of capsid proteins and DNA by a competitive antagonism with amino acid arginine, which is an essential amino acid for some viruses, and also by promoting the increase of arginase, increasing the catabolism of arginine. Although there is evidence of the importance of L-lysine in viral control, more studies are needed, with a view to new antiviral therapies.

show abstract

Herpes‐like skin lesion after AstraZeneca vaccination for COVID‐19: A case report

Abstract: Recurrent herpes simplex virus or varicella zoster virus infection should be considered as one of the rare complications after AstraZeneca vaccination for COVID‐19.

Cited by 22 publications

References 11 publications

Global prevalence and clinical manifestations of cutaneous adverse reactions following COVID‐19 vaccination: A systematic review and meta‐analysis

Global prevalence and clinical manifestations of cutaneous adverse reactions following COVID‐19 vaccination: A systematic review and meta‐analysis

Potential risk factors for Varicella‐zoster virus reactivation after COVID‐19 vaccination

L‐lysine: Its antagonism with L‐arginine in controlling viral infection. Narrative literature review

Contact Info

Product

Resources

About